ARV-771 is primarily used in the field of cancer research and drug development. It functions as a proteolysis-targeting chimera (PROTAC), a novel class of compounds designed to degrade specific proteins within cells. Its main application lies in targeting and degrading BET (bromodomain and extra-terminal) proteins, which play a critical role in regulating gene expression and are often implicated in cancer progression. By inducing the degradation of these proteins, ARV-771 has shown potential in inhibiting tumor growth and overcoming resistance to traditional therapies. It is particularly studied in the context of hematologic malignancies and solid tumors, offering a promising approach for targeted cancer treatment.